<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02462031</url>
  </required_header>
  <id_info>
    <org_study_id>KD101-102</org_study_id>
    <nct_id>NCT02462031</nct_id>
  </id_info>
  <brief_title>To Evaluate the Safety, Tolerability, PK, PK-PD Relation of KD101 in the Fed State in Obese or Overweight Subjects</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Single or Multiple Ascending Dose Phase I Clinical Trial to Evaluate the Safety, Tolerability, PK, PK-PD Relation of KD101 in the Fed State in Obese or Overweight Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kwang Dong Pharmaceutical co., ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kwang Dong Pharmaceutical co., ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To Evaluate the safety, tolerability and pharmacokinetic property after KD101 multiple oral
      dosing in the fed state in obese or overweight subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      dose block-randomized, double-blinded, placebo controlled, single or multiple ascending dose
      study. AEs, PE, Vital signs, ECGs and Clinical lab tests

        -  Part I : multiple dose study (KD101 or placebo) / male and female

        -  Part II : single dose study (KD101) / male only
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic parameters - Cmax</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>Cmax (Maximum concentration of drug in plasma)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic parameters - PBMCs</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>PBMC (Peripheral blood mononuclear cell)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>KD101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>KD101 placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KD101</intervention_name>
    <description>200mg, 400mg, 800mg, 1400mg</description>
    <arm_group_label>KD101</arm_group_label>
    <other_name>KD101 soft capsule 200mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>200mg, 400mg, 800mg</description>
    <arm_group_label>KD101 placebo</arm_group_label>
    <other_name>KD101 soft capsule 200mg placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or Female adults aged 20 to 55 at screening (Part II : Male adults aged 20 to 55
             at screening)

          -  Healthy volunteer whose BMI ≥ 27 (Part II : Healthy volunteer whose BMI ≥ 18)

          -  Female who are not pregnancy possibility or Male/Female who can abstinence or
             contraception during clinical trials

        Exclusion Criteria:

          -  Subjects who had clinically significant disease history
             (liver,kidney,nervous,pulmonary,endocrinal,urinary,cardiovascular,musculoskeletal,ment
             al system,blood,tumor) or diagnosed within 1 month from screening

          -  Subjects who had gastrointestinal disease(Crohn's disease, ulcer, acute/chronic
             pancreatitis) that affect the absorption of test drug or gastrointestinal operation
             (However, appendectomy, herniotomy induced by acute appendicitis are excluded)

          -  Subjects who had following history. [myocardial infarction (diagnosed by cardiac
             enzyme and/or diagnostic ECG), cerebral infarction/stroke, arrhythmia needed to
             medical treatment, unstable angina, pulmonary hypertension]

          -  Subjects who had positive result to Human Immunodeficiency Virus, Hepatitis B virus,
             Hepatitis C virus during screening

          -  Subjects who had allergy history (ex. allergy for aspirin, antibiotics, etc) or had
             clinically-significant allergy

          -  Subjects whose systolic BP was &lt;85mmHg or &gt;145mmHg, or diastolic BP was &lt;50mmHg or
             &gt;95mmHg, or pulse was &gt;100/min after 3 minute-seating position. (BP can be re-measured
             twice at leat 5 minute-interval)

          -  Subjects who would take prescribed/oriental drug(within 2 weeks from the first dosing
             day) or OTC drug or vitamines (within 1 weeks from the first dosing day)

          -  Subjects who drink over than 21 unit (1 unit = 10g of pure alcohol) or cannot quit
             drinking alcohol during clinical trial period

          -  Subjects who ate following food within 2 days from the first dosing day or cannot quit
             following food [grapefruit-contain food, caffein-contain food(coffee, green tea, black
             tea, soft drink, coffee milk, energy drink)]

          -  Subjects who didn't agree contraception

          -  Subjects who didn't agree to quit smoke

          -  Subjects who donated his/her blood within 2 months (whole blood) / 1 month (apheresis)
             or who took transfusion within 1 month

          -  Subjects who participated another clinical trials within 3 months from first dosing
             day. (The clinical trial completion day is defined as the last dosing day of past
             clinical trial)

          -  Subjects who are not adequate to this trial by lab examination and another reasons

          -  Subjects who weighed loss more than 5kg in 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Howard Lee, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howard Lee, Professor</last_name>
      <phone>82 2 3668 7602</phone>
      <email>leehwd@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2015</study_first_submitted>
  <study_first_submitted_qc>June 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2015</study_first_posted>
  <last_update_submitted>June 2, 2015</last_update_submitted>
  <last_update_submitted_qc>June 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

